Genentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine

Go back to Genentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine
Roche Holding AG Basel American Depositary Shares (AMEX: RHHBY) Delayed: 59.11 --0 (-0%)
Previous Close $59.11    52 Week High $35.13 
Open $59.11    52 Week Low $28.10 
Day High $59.49    P/E N/A 
Day Low $58.83    EPS $0.00 
Volume 1,311,205